ROCKVILLE, Md., Nov. 2, 2011 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its third quarter financial results for the quarter ended September 24, 2011. The Company’s net loss from continuing operations for the third quarter of 2011 was $2.9 million, or $0.07 per share, compared to net income of $5.1 million, or $0.12 per share, for the third quarter of 2010. Nabi also had $3.0 million, or $0.07 per share, in net income from discontinued operations for the third quarter ended September 24, 2011. Nabi had no results from discontinued operations in the third quarter of 2010.
